Gastrointestinal stromal tumors (GISTs)

Current Opinion in Gastroenterology

Volumn 20, Issue 2, 2004, Pages 89-94

  Saund, Mandeep S ^a   Demetri, George D ^b   Ashley, Stanley W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gastrointestinal stromal tumor; GIST; Imatinib mesylate; KIT; PET scan

Indexed keywords

IMATINIB; ONCOPROTEIN; TYROSINE KINASE RECEPTOR;

ASPIRATION BIOPSY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM INJURY; ECHOGRAPHY; ENDOSCOPY; EVALUATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MITOSIS; MUTATIONAL ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 1542350259     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200403000-00007     Document Type: Review

References (37)

1. Mazur MT, Clark HB: Gastric stromal tumors: Reappraisal of histogenesis. Am J Surg Pathol 1983, 7:507-519.
2. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
3. Bauer S, Corless CL, Heinrich MC, et al.: Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol 2003, 51:261-265. Case report suggesting that GISTs with even very low expression of KIT may respond to imatinib.
4. Joensuu H, Fletcher C, Dimitrijevic S, et al.: Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002, 3:655-664. Very complete review on all aspects of GISTs.
5. Miettinen M, Majidi M, Lasota J: Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): A review. Eur J Cancer 2002, 38(suppl 5):S39-S51.
6. Davila RE, Faigel DO: GI stromal tumors. Gastrointest Endosc 2003; 58:80-88. A nice summary of the current status of endoscopic diagnosis and therapy for GISTs.
7. Roberts PJ, Eisenberg B: Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer 2002, 38(suppl 5):S37-S38.
8. Greenson JK: Gastrointestinal stromal tumors and other mesenchymal lesions of the gut. Mod Pathol 2003, 16:366-375. An excellent discussion of the pathology of GISTs and the histologic distinction of these tumors from other mesanchymal tumors of the gut.
9. Tornoczky TKE, Pajor L: Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumors. J Clin Pathol 2003, 56:363-367. An important report emphasizing the potential of even histologically very low grade GISTs to metastasize.
10. Rossi CR, Mocelin S, Mencarelli R, et al.: Gastrointestinal stromal tumors: From a surgical to a molecular approach. Int J Cancer 2003, 107:171-176.
11. Demetri G: Identification and treatment of chemoresistant inoperable or metastatic GIST: Experience with selective inhibitor imatinib mesylate (STI571). Euro J Cancer 2002, 38(suppl 5):S52-S59.
12. Dematteo RP, Maki RG, Antonescu C, et al.: Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg 2003, 40:144-193. Another superb review on these tumors, placing therapy in the context of other molecularly targeted therapies.
13. Yan H, Marchettini P, Acherman YI, et al.: Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol 2003, 26:221-228.
14. Okai T, Minamoto T, Ohtsubo K, et al.: Endosonographic evaluation of c-kit-positive gastrointestinal stromal tumor. Abdom Imaging 2003, 28:301-307. A useful description of the endoscopic ultrasound features of these tumors focusing on their distinction from other submucosal lesions.
15. Rader AE, Avery A, Wait CL, et al.: Fine needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis. Cancer 2001, 93:269-274.
16. Ghanem N, Altehoefer C, Furtwangler A, et al.: Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003, 13:1669-1678. Insightful description of the computed tomography characteristics and limitations of such studies in staging GISTs.
17. Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(suppl 5):S60-S65.
18. Stroobants S, Goeminne J, Seegers M, et al.: 18 FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 2003, 39:2012-2020. An interesting study evaluating the use of PET scanning in predicting the GIST response to imatinib.
19. Fujimoto Y, Nakanishi Y, Yoshimura K, et al.: Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: Analysis of results in 140 surgically resected patients. Gastric Cancer 2003, 6:39-48. One of the larger studies examining pathologic prognostic factors in these tumors.
20. Schneider-Stock R, Boltze C, Lasota J, et al.: High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003, 21:1688-1697.
21. Dei Tos AP: The reappraisal of gastrointestinal stromal tumors: From Stout to the KIT revolution. Virchows Arch 2003, 442:421-428.
22. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459-465. Excellent summary of an NIH Consensus Conference regarding prognostic markers in GISTs.
23. Singer S, Rubin BP, Lux ML, et al.: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002, 20:3898-3905. Important study placing mutation analysis in the context of other prognostic markers.
24. Wong NA, Young R, Malcomson RD, et al.: Prognostic indicators for gastrointestinal stromal tumours: A clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003, 43:118-126.
25. Medina-Franco H, Ramos-De la Medina A, Cortes-Gonzalez R, et al.: Expression of p53 and proliferative index as prognostic factors in gastrointestinal sarcomas. Ann Surg Oncol 2003, 10:190-195.
26. Takahashi R, Tanaka S, Kitadai Y, et al.: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003, 64:266-274.
27. Bumming P, Andersson J, Meis-Kindblom JM, et al.: Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients. Br J Cancer 2003, 89:460-464. One of the first reports using imatinib in the adjuvant and neoadjuvant setting.
28. Shima Y, Horimi T, Ishikawa T, et al.: Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg 2003, 10:77-80. A small series of major hepatic resections for metastatic GIST suggesting that this aggressive approach is of benefit.
29. Sawaki A, Ohashi K, Yamao K, et al.: Effect of a tyrosine kinase inhibitor STI571 in a patient with hepatic metastases from a duodenal gastrointestinal stromal tumor. J Gastroenterol 2003, 38:690-694.
30. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-460. Results of the US-Finland study of imatinib in advanced GISTs, including considerable new data on the benefits, toxicity, and monitoring of this therapy.
31. van Oosterom AT, Judson IR, Verweij J, et al.: Update of phase I study of imatinib (STI571 ) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002, 38(suppl 5):S83-S87.
32. Kanda T, Ohashi M, Makino S, et al.: A successful case of oral molecularly targeted therapy with imatinib for peritoneal metastasis of a gastrointestinal stromal tumor. Int J Clin Oncol 2003, 8:180-183.
33. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
34. Heinrich MC, Corless CL, Blanke C, et al.: KIT mutational analysis predicts clinical response to ST1571 in patients with metastatic gastrointestinal stromal tumors (GISTs) [Abstract]. Proc ASCO 2002, 21:6. Interesting abstract suggesting that resistance to imatinib may be predicted by mutational analysis.
35. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571 ) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
36. Manning WC, Bello CL, Deprimo SE, et al.: Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant stromal tumors [Abstract]. Proc ASCO 2003, 22:768. Abstract suggesting that tumors resistant to imatinib may respond to one of the newer tyrosine kinase inhibitors.
37. Demetri GD: personal communication.